---
title: Insights into treatment of patients with mycosis fungoides or SÃ©zary syndrome
  using mogamulizumab
date: '2025-02-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39894454/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250203170919&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: MAVORIC demonstrated greater efficacy with mogamulizumab
  vs. vorinostat in relapsed/refractory patients with CTCL, including those with more
  advanced disease. Concomitant steroid use improved ORR and PFS but did not impact
  vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated
  patients that developed lymphopenia than those that did not. A higher percentage
  of patients with MAR had an overall response than those without ...'
disable_comments: true
---
CONCLUSIONS: MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without ...